← All compounds
Well Researched

CJC-1295 with DAC

Long-Acting Growth Hormone Releasing Hormone Analog | Extended Release

CJC-1295 with DAC (Drug Affinity Complex) is a modified version of growth hormone releasing hormone (GHRH) engineered for extended duration. The addition of DAC technology extends the half-life to 6-8 days, providing continuous growth hormone elevation rather than pulsatile release. This long-acting formulation offers convenience but differs significantly from natural GH secretion patterns.

Daily dose

Not daily - 1-2mg per week

Frequency

1-2 times weekly

Cycle length

8-12 weeks

Storage

2-8°C (refrigerated)

Key benefits

Convenient weekly dosing, sustained GH/IGF-1 elevation, significant body composition changes

How it works

DAC technology binds to albumin, extending half-life to 6-8 days and providing continuous GHRH receptor stimulation

Dosage protocols

Goal

Conservative Anti-Aging

Dose

1mg · Once weekly

Route

Subcutaneous

Goal

Standard Protocol

Dose

2mg · Once weekly

Route

Subcutaneous

Goal

Split Dosing

Dose

1mg · Twice weekly (Mon/Thu)

Route

Subcutaneous

Goal

Loading Protocol

Dose

2mg first week, then 1mg · Weekly

Route

Subcutaneous

Research indications

growth Hormone

Sustained GH Elevation — Provides continuous growth hormone release for 6-8 days per injection
IGF-1 Optimization — Significantly elevates IGF-1 levels for extended periods
Convenience Protocol — Weekly dosing schedule ideal for those seeking simple administration

body Composition

Fat Loss Enhancement — Continuous GH elevation promotes lipolysis and fat metabolism
Lean Mass Gains — Sustained anabolic environment supports muscle protein synthesis
Body Recomposition — Simultaneous fat loss and muscle gain potential

anti Aging

Skin Rejuvenation — Extended GH/IGF-1 elevation may improve skin elasticity and thickness
Energy Levels — Users report improved vitality and reduced fatigue
Recovery Enhancement — Accelerated healing and recovery from exercise or injury

Administration

injectable

Interactions

Use Caution
Ipamorelin — Can be combined but continuous GH elevation from DAC version may reduce synergistic benefits of pulsatile protocols
Use Caution
GHRP-6 — GHRP pulse effects are diminished when combined with continuous GH elevation from CJC-1295 DAC
Avoid Combination
CJC-1295 — Never combine different CJC-1295 variants - choose based on desired release pattern
Avoid Combination
MK-677 — Both provide continuous GH elevation - combination may lead to excessive and unnatural GH levels
Avoid Combination
Tesamorelin — Both target GHRH receptors but with conflicting release patterns. Tesamorelin promotes pulsatile GH release while DAC provides continuous stimulation, disrupting natural GH rhythms and accelerating receptor downregulation.
Avoid Combination
HGH — Combining with exogenous HGH defeats the purpose and may suppress natural production
Use Caution
Sermorelin — Both work through GHRH pathway - CJC-1295 DAC is already more potent and long-lasting

Safety notes

Higher side effect incidence than pulsatile protocols

Common: Water retention, joint pain, carpal tunnel symptoms

Monitor for signs of excessive GH: jaw growth, hand/feet enlargement

Not suitable for those with diabetes or cancer history

May worsen sleep apnea in predisposed individuals

Regular IGF-1 monitoring recommended for long-term use

Research studies

Comparative Pharmacokinetics: DAC vs Non-DAC Variants (2015)

Human | Crossover design | 30 days each arm

DAC version showed 120-hour half-life versus 30-minute half-life of non-DAC, but non-DAC preserved more physiological GH patterns.

Long-term Effects on GH/IGF-1 Axis (2012)

Animal model | 6 months | Weekly dosing

Chronic administration led to sustained IGF-1 elevation but some evidence of reduced GH pulse amplitude, suggesting partial desensitization.

Dose-Response Relationship of CJC-1295 DAC (2008)

Human | Multiple doses | 90 days | 48 subjects

Established optimal dosing at 1-2mg weekly, showing dose-dependent IGF-1 increases but also higher side effect incidence at doses above 2mg.

Prolonged Growth Hormone Elevation with CJC-1295 DAC (2006)

Human | 30-60mcg/kg | Single injection | 12 subjects

Demonstrated sustained GH and IGF-1 elevation for 6-10 days following a single injection, with peak levels 2-4x baseline maintained throughout.

Related compounds

CJC-1295 (without DAC)IpamorelinCJC-1295 (no DAC) / Ipamorelin ProtocolTesamorelin